TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
Cyprus Mail on MSN
Diabetes drugs could treat Alzheimer’s but ‘timing is key’
By Athena VlachouDrugs used to treat metabolic disorders, such as Type 2 diabetes, alleviate symptoms of Alzheimer’s disease ...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® (alirocumab) as an adjunct to diet and other low-density ...
NEW ORLEANS -- Treatment with the PCSK9 inhibitor alirocumab (Praluent) safely lowered LDL cholesterol versus placebo in transplant patients already on rosuvastatin, but did not reduce the development ...
Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent ® (alirocumab) - Praluent continues to be available to patients in the U.S. - Paris, ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback